Montelukast Mylan Generics

Montelukast, the active ingredient in Montelukast Mylan Generics, is a leukotriene receptor antagonist presented as a tablet for oral use. It helps control asthma symptoms, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children. GNH USA supplies Montelukast Mylan Generics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to manage chronic respiratory conditions. - Asthma: reduces the frequency of asthma attacks and improves overall lung function. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity, allowing better exercise tolerance.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often reported during early treatment. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional irritation of the throat. - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired. - Nausea: mild upset stomach.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis requiring immediate medical attention. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Bronchospasm: paradoxical worsening of breathing. - Blood dyscrasias: rare cases of eosinophilia or neutropenia.

Before initiating therapy, consider the following safety measures. - Liver function assessment: evaluate hepatic status, especially in patients with known liver disease. - Neuropsychiatric monitoring: watch for mood changes, depression or suicidal ideation. - Acute asthma attacks: do not use as rescue medication; provide a fast‑acting bronchodilator instead. - Hypersensitivity: avoid if the patient has known allergy to montelukast or any tablet excipients. - Drug interactions: review concomitant medications that may alter montelukast levels. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase montelukast plasma concentrations. - Phenobarbital or rifampicin: potent inducers that can reduce therapeutic levels. - Antidepressants (e.g., fluoxetine) combined with other leukotriene antagonists: heightened risk of neuropsychiatric effects.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR; monitor coagulation parameters. - Other leukotriene modifiers (zafirlukast, zileuton): additive effects on leukotriene pathways. - Oral contraceptives: minor impact on hormone levels; observe for menstrual changes. - Theophylline: monitor for increased side‑effects, though interaction is limited. - Antifungal agents (e.g., fluconazole): may modestly raise montelukast levels.